A new jab, that could end the agony of back pain, has got an approval from European regulators.
During experiments, the Cimzia jabs showed rapid improvements in pain, stiffness and mobility, the Daily Express reported.
The breakthrough fortnightly injection can allow back pain sufferers to enjoy activities and run errands they couldn't do before.
Sufferers can experience increased pain when resting which improves with exercise, painful inflammation of tendons and ligaments, arthritis, sore red eyes known as uveitis, and inflammatory bowel disease.
Dr Stefan Siebert, a senior lecturer in rheumatology at the University of Glasgow, said with advances in imaging technology, better diagnostic criteria and new treatments they now have the opportunity to improve patients' symptoms and avert long-term disability.
Cimzia is administered every fortnight but after two jabs it can be administered monthly.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
